• If you are wondering whether Danaher stock at around US$182.67 still offers value, or if the recent move has already priced in the key stories, this article breaks down what the current price might be implying.
• Over the past week the stock has risen 6.2%, adding to a 4.3% gain over the last month, even though the year to date return stands at a decline of 20.7% and the 1 year return is a decline of 3.1%.
• Recent news coverage has focused on Danaher's positioning within life sciences and diagnostics, as investors weigh the stock's role in areas like bioprocessing tools and healthcare research. This attention helps explain why sentiment can shift quickly around the stock and contribute to short term price swings.
• Danaher currently has a valuation score of 3 out of 6. The sections that follow will compare what different valuation approaches suggest about the stock and then finish with a broader way to think about value beyond the headline numbers.

Approach 1: Danaher Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes projected future cash flows from a company and discounts them back to today, aiming to estimate what those cash flows are worth in present value terms.

For Danaher, the latest twelve month Free Cash Flow (FCF) is about $5.1b. Analysts and model estimates project FCF of $5.7b in 2026 and $8.1b in 2030, with later years extrapolated using Simply Wall St assumptions rather than new analyst forecasts. All of these figures are in $ and are fed into a 2 Stage Free Cash Flow to Equity model that applies a discount rate to each year’s projected cash flow.

On this basis, the DCF model points to an estimated intrinsic value of about $225.80 per share. Compared with the recent share price of about $182.67, this implies the stock is 19.1% below that DCF estimate. Under these assumptions, the stock screens as undervalued on cash flow grounds.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Danaher is undervalued by 19.1%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Danaher Price vs Earnings

For a profitable company, the P/E ratio is a useful yardstick because it tells you how much you are paying today for each dollar of current earnings. It is a quick way to compare what the market is willing to pay for different businesses that are already generating profits.

What counts as a "normal" or "fair" P/E depends on what investors expect for future growth and how much risk they see in the business. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk tends to line up with a lower multiple.

Danaher currently trades on a P/E of 35.18x. That sits slightly above the Life Sciences industry average of 34.27x, yet below the peer group average of 39.87x. Simply Wall St then goes a step further with its proprietary "Fair Ratio" of 29.42x for Danaher, which reflects factors like earnings growth profile, industry, profit margins, market cap and company specific risks. This Fair Ratio is often more useful than a simple peer or industry comparison because it tailors the expected multiple to the company rather than treating all stocks as interchangeable. Comparing the current 35.18x P/E with the 29.42x Fair Ratio suggests the stock screens as overvalued on this measure.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Danaher Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives bring this to life by letting you attach a clear story about Danaher to your own forecasts for future revenue, earnings and margins, link that story to a Fair Value, and then compare it with the current price, all inside Simply Wall St’s Community page where millions of investors share their views. For example, one investor might build a Narrative around the higher analyst fair value of about US$310 per share with stronger expectations for bioprocess recovery and Masimo integration. Another might anchor on the lower fair value of about US$200 with more cautious assumptions on growth. As fresh news, earnings or guidance arrive, those Narratives and their Fair Values update automatically to help you decide whether the gap between price and value supports buying, holding or waiting.

Do you think there's more to the story for Danaher? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.